Asceneuron discovers and develops groundbreaking therapeutics for neurodegenerative disorders with high unmet medical needs: orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
News & Events
-
Press releases
Asceneuron Joins CPAD Consortium
Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium
-
Press releases
Asceneuron Expands Scientific Advisory Board
Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
-
Press releases
Abbas Hussain Appointed as Chair of Asceneuron
Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron
-
Press releases
Asceneuron Welcomes Barbara Angehrn Pavik as New CEO
Asceneuron Welcomes Barbara Angehrn Pavik as New CEO as It Gears Up for Next Phase of Growth
-
Event
Asceneuron to attend BIO International Convention in Boston
The Asceneuron team will attend the BIO International Convention to be held June 5-8 in Boston, MA.
-
Event
Asceneuron will present at AD/PD 2023
The Asceneuron team will attend AD/PD 2023, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. from...
-
Event
Asceneuron to attend Bio-Europe Spring event
Asceneuron's CEO Dirk Beher will attend the Bio Europe Spring partnering event held on March 20-22, 2023 in Basel, Switzerland.
-
Press releases
Ferrer acquires worldwide rights to ASN90, exclusively to treat PSP
Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)
-
Event
Asceneuron at the Annual Biotech in Europe Forum
Asceneuron will participate in the 22nd Annual Biotech in Europe Forum for global partnering and investment (BEF), being held on...